{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:45Z","timestamp":1761238305276},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00347-016-0306-9","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T06:39:06Z","timestamp":1467268746000},"page":"1036-1045","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Makula-Atrophie bei feuchter altersabh\u00e4ngiger Makuladegeneration"],"prefix":"10.1007","volume":"113","author":[{"given":"J. G.","family":"Garweg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"issue":"5","key":"306_CR1","doi-asserted-by":"crossref","first-page":"e0126636","DOI":"10.1371\/journal.pone.0126636","volume":"10","author":"F Grassmann","year":"2015","unstructured":"Grassmann F, Fleckenstein M, Chew EY, Strunz T, Schmitz-Valckenberg S, G\u00f6bel AP, Klein ML, Ratnapriya R, Swaroop A, Holz FG, Weber BH (2015) Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. PLoS ONE 10(5):e0126636","journal-title":"PLoS ONE"},{"issue":"12","key":"306_CR2","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.ophtha.2014.06.034","volume":"121","author":"Z Wu","year":"2014","unstructured":"Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2014) Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology 121(12):2415\u20132422","journal-title":"Ophthalmology"},{"key":"306_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2015.04.003","volume":"160","author":"AR Rudnicka","year":"2015","unstructured":"Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, Cook DG, Owen CG (2015) Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis. Am J Ophthalmol 160:85\u201393.e3","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"306_CR4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","volume":"132","author":"EY Chew","year":"2014","unstructured":"Chew EY, Clemons TE, Agr\u00f3n E, Sperduto RD, Sangiovanni JP, Davis MD, Ferris FL 3rd, Age-Related Eye Disease Study Research Group (2014) Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol 132(3):272\u2013277","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"306_CR5","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106\u2013e116","journal-title":"Lancet Glob Health"},{"issue":"2","key":"306_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.4266","volume":"232","author":"M Lookeren Campagne van","year":"2014","unstructured":"Lookeren Campagne M van, LeCouter J, Yaspan BL, Ye W (2014) Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 232(2):151\u2013164","journal-title":"J Pathol"},{"issue":"1","key":"306_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2415-15-9","volume":"15","author":"S Sengupta","year":"2015","unstructured":"Sengupta S, Nguyen AM, Landingham SW van, Solomon SD, Do DV, Ferrucci L, Friedman DS, Ramulu PY (2015) Evaluation of real-world mobility in age-related macular degeneration. BMC Ophthalmol 15(1):9. doi:10.1186\/1471-2415-15-9","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"306_CR8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/eye.2014.189","volume":"28","author":"G Barteselli","year":"2014","unstructured":"Barteselli G, Gomez ML, Doede AL, Chhablani J, Gutstein W, Bartsch DU, Dustin L, Azen SP, Freeman WR (2014) Visual function assessment in simulated real-life situations in patients with age-related macular degeneration compared to normal subjects. Eye (Lond) 28(10):1231\u20131238","journal-title":"Eye (Lond)"},{"issue":"8","key":"306_CR9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/OPX.0b013e3182962318","volume":"90","author":"T Butt","year":"2013","unstructured":"Butt T, Dunbar HM, Morris S, Orr S, Rubin GS (2013) Patient and public preferences for health states associated with AMD. Optom Vis Sci 90(8):855\u2013860","journal-title":"Optom Vis Sci"},{"issue":"7","key":"306_CR10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/eye.2014.103","volume":"28","author":"A Rees","year":"2014","unstructured":"Rees A, Zekite A, Bunce C, Patel PJ (2014) How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration? Eye (Lond) 28(7):832\u2013837","journal-title":"Eye (Lond)"},{"key":"306_CR11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.preteyeres.2013.07.003","volume":"37","author":"D Ardeljan","year":"2013","unstructured":"Ardeljan D, Chan CC (2013) Aging is not a disease: distinguishing age-related macular degeneration from aging. Prog Retin Eye Res 37:68\u201389","journal-title":"Prog Retin Eye Res"},{"key":"306_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000358536","volume":"53","author":"MA Zarbin","year":"2014","unstructured":"Zarbin MA, Casaroli-Marano RP, Rosenfeld PJ (2014) Age-related macular degeneration: clinical findings, histopathology and imaging techniques. Dev Ophthalmol 53:1\u201332","journal-title":"Dev Ophthalmol"},{"issue":"1","key":"306_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/bjophthalmol-2015-306972","volume":"100","author":"J Hanus","year":"2015","unstructured":"Hanus J, Zhao F, Wang S (2015) Current therapeutic development in atrophic age-related macular degeneration. Br J Ophthalmol 100(1):122\u2013127","journal-title":"Br J Ophthalmol"},{"key":"306_CR14","first-page":"532487","volume":"2014","author":"S Camelo","year":"2014","unstructured":"Camelo S (2014) Potential sources and roles of adaptive immunity in age-related macular degeneration: shall we rename AMD into Autoimmune macular disease? Autoimmune Dis 2014:532487","journal-title":"Autoimmune Dis"},{"issue":"9","key":"306_CR15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/IAE.0b013e318285cd9e","volume":"33","author":"PS Muether","year":"2013","unstructured":"Muether PS, Neuhann I, Buhl C, Hermann MM, Kirchhof B, Fauser S (2013) Intraocular growth factors and cytokines in patients with dry and neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 33(9):1809\u20131814","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"306_CR16","first-page":"485","volume":"7","author":"P Tranos","year":"2013","unstructured":"Tranos P, Vacalis A, Asteriadis S, Koukoula S, Vachtsevanos A, Perganta G, Georgalas I (2013) Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther 7:485\u2013490","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"306_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"M Tolentino","year":"2011","unstructured":"Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56(2):95\u2013113","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"306_CR18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/ICU.0b013e32835fefee","volume":"24","author":"AW Scott","year":"2013","unstructured":"Scott AW, Bressler SB (2013) Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 24(3):190\u2013196","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"306_CR19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, Mc Allister IL, Essex RW, Morlet N, Hunyor AP, Fight Retinal Blindness Study Group (2015) Long-term outcomes of treatment of Neovascular age-related macular degeneration: data from an observational study. Ophthalmology 122(9):1837\u20131845","journal-title":"Ophthalmology"},{"issue":"8","key":"306_CR20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","volume":"132","author":"GS Ying","year":"2014","unstructured":"Ying GS, Kim BJ, Maguire MG, Huang J, Daniel E, Jaffe GJ, Grunwald JE, Blinder KJ, Flaxel CJ, Rahhal F, Regillo C, Martin DF, CATT Research Group (2014) Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 132(8):915\u2013921","journal-title":"JAMA Ophthalmol"},{"key":"306_CR21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, Zhang K (2015) Macular atrophy progression and 7\u2011year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159:915\u2013924.e2","journal-title":"Am J Ophthalmol"},{"key":"306_CR22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","volume":"159","author":"C Sch\u00fctze","year":"2015","unstructured":"Sch\u00fctze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2015) Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 159:1100\u20131114.e1","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"306_CR23","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M (2012) Targeted deletion of Vegfa in adult mice induces vision loss. J\u00a0Clin Invest 122(11):4213\u20134217","journal-title":"J Clin Invest"},{"issue":"4","key":"306_CR24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.preteyeres.2008.05.002","volume":"27","author":"S Grisanti","year":"2008","unstructured":"Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27(4):372\u2013390","journal-title":"Prog Retin Eye Res"},{"key":"306_CR25","first-page":"CD005139","volume":"8","author":"SD Solomon","year":"2014","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS (2014) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 8:CD005139","journal-title":"Cochrane Database Syst Rev"},{"key":"306_CR26","first-page":"CD011230","volume":"9","author":"L Moja","year":"2014","unstructured":"Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D\u2019Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, M\u00fchlbauer B, P\u00fcntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 9:CD011230","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"306_CR27","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1172\/JCI65509","volume":"122","author":"SE Quaggin","year":"2012","unstructured":"Quaggin SE (2012) Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122(11):3849\u20133851","journal-title":"J Clin Invest"},{"issue":"7","key":"306_CR28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/IAE.0000000000000081","volume":"34","author":"M Young","year":"2014","unstructured":"Young M, Chui L, Fallah N, Or C, Merkur AB, Kirker AW, Albiani DA, Forooghian F (2014) Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 34(7):1308\u20131315","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"4","key":"306_CR29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","volume":"122","author":"JE Grunwald","year":"2015","unstructured":"Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, Comparison of Age-related Macular Degeneration Treatments Trials Research Group (2015) Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 122(4):809\u2013816","journal-title":"Ophthalmology"},{"issue":"6","key":"306_CR30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/eye.2011.66","volume":"25","author":"CH Meyer","year":"2011","unstructured":"Meyer CH, Holz FG (2011) Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and Bevacizumab. Eye (Lond) 25(6):661\u2013672","journal-title":"Eye (Lond)"},{"issue":"11","key":"306_CR31","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00417-012-2123-4","volume":"250","author":"PK Kaiser","year":"2012","unstructured":"Kaiser PK, Cruess AF, Bogaert P, Khunti K, Kelly SP (2012) Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 250(11):1563\u20131571","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"306_CR32","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1167\/iovs.13-13769","volume":"55","author":"HJ Shin","year":"2014","unstructured":"Shin HJ, Shin KC, Chung H, Kim HC (2014) Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci 55(4):2403\u20132411","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"306_CR33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","volume":"39","author":"AC Bird","year":"1995","unstructured":"Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, Jong PT de, Klaver CC, Klein BE, Klein R et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39(5):367\u2013374","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"306_CR34","first-page":"671","volume":"119","author":"K Takahashi","year":"2015","unstructured":"Takahashi K, Shiraga F, Ishida S, Kamei M, Yanagi Y, Yoshimura N (2015) Diagnostic criteria for atrophic age-related macular degeneration. Nippon Ganka Gakkai Zasshi 119(10):671\u2013677","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"306_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12671","author":"PC Lim","year":"2015","unstructured":"Lim PC, Layton CJ (2015) Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design. Clin Experiment Ophthalmol. doi:10.1111\/ceo.12671","journal-title":"Clin Experiment Ophthalmol"},{"key":"306_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM (2015) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1\u201324","journal-title":"Prog Retin Eye Res"},{"key":"306_CR37","doi-asserted-by":"publisher","DOI":"10.3791\/53382","author":"S McHarg","year":"2015","unstructured":"McHarg S, Brace N, Bishop PN, Clark SJ (2015) Enrichment of Bruch\u2019s membrane from human donor eyes. J\u00a0Vis Exp. doi:10.3791\/53382","journal-title":"J Vis Exp"},{"issue":"9","key":"306_CR38","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/bjo.2010.199216","volume":"95","author":"IA Bhutto","year":"2011","unstructured":"Bhutto IA, Baba T, Merges C, Juriasinghani V, McLeod DS, Lutty GA (2011) C\u2011reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration. Br J Ophthalmol 95(9):1323\u20131330","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"306_CR39","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","volume":"73","author":"A Kauppinen","year":"2016","unstructured":"Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K (2016) Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 73(9):1765\u20131786","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"306_CR40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","volume":"33","author":"I Bhutto","year":"2012","unstructured":"Bhutto I, Lutty G (2012) Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex. Mol Aspects Med 33(4):295\u2013317","journal-title":"Mol Aspects Med"},{"key":"306_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ophtha.2015.09.016","volume":"123","author":"FA Folgar","year":"2015","unstructured":"Folgar FA, Yuan EL, Sevilla MB, Chiu SJ, Farsiu S, Chew EY, Toth CA, Age Related Eye Disease Study 2 Ancillary Spectral-Domain Optical Coherence Tomography Study Group (2015) Drusen volume and retinal pigment epithelium abnormal thinning volume predict 2\u2011year progression of age-related macular degeneration. Ophthalmology 123:39\u201350.e1 (pii: S0161-6420(15)01038-6)","journal-title":"Ophthalmology"},{"issue":"4","key":"306_CR42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ajo.2014.06.021","volume":"158","author":"NA Nathoo","year":"2014","unstructured":"Nathoo NA, Or C, Young M, Chui L, Fallah N, Kirker AW, Albiani DA, Merkur AB, Forooghian F (2014) Optical coherence tomography-based measurement of drusen load predicts development of advanced age-related macular degeneration. Am J Ophthalmol 158(4):757\u2013761 (e1)","journal-title":"Am J Ophthalmol"},{"key":"306_CR43","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajo.2014.01.023","volume":"157","author":"S Boddu","year":"2014","unstructured":"Boddu S, Lee MD, Marsiglia M, Marmor M, Freund KB, Smith RT (2014) Risk factors associated with reticular pseudodrusen versus large soft drusen. Am J Ophthalmol 157:985\u2013993.e2","journal-title":"Am J Ophthalmol"},{"key":"306_CR44","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ (2015) Subretinal Hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology 122:1846\u201353.e5","journal-title":"Ophthalmology"},{"issue":"1","key":"306_CR45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10408363.2014.968703","volume":"52","author":"D Chiras","year":"2015","unstructured":"Chiras D, Kitsos G, Petersen MB, Skalidakis I, Kroupis C (2015) Oxidative stress in dry age-related macular degeneration and exfoliation syndrome. Crit Rev Clin Lab Sci 52(1):12\u201327","journal-title":"Crit Rev Clin Lab Sci"},{"key":"306_CR46","unstructured":"Kim SY (2015) Retinal phagocytes in age-related macular degeneration. Macrophage (Houst) 2(1):e698"},{"issue":"6","key":"306_CR47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00018-010-0597-y","volume":"68","author":"A Salminen","year":"2011","unstructured":"Salminen A, Ojala J, Kaarniranta K (2011) Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell Mol Life Sci 68(6):1021\u20131031","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"306_CR48","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.cellsig.2013.06.007","volume":"25","author":"A Kauppinen","year":"2013","unstructured":"Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A (2013) Antagonistic crosstalk between NF-\u03baB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 25(10):1939\u20131948","journal-title":"Cell Signal"},{"issue":"7","key":"306_CR49","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4161\/auto.24546","volume":"9","author":"K Kaarniranta","year":"2013","unstructured":"Kaarniranta K, Sinha D, Blasiak J, Kauppinen A, Ver\u00e9b Z, Salminen A, Boulton ME, Petrovski G (2013) Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration. Autophagy 9(7):973\u2013984","journal-title":"Autophagy"},{"key":"306_CR50","first-page":"1","volume":"2","author":"M Takalo","year":"2013","unstructured":"Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A (2013) Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegener Dis 2:1\u201314","journal-title":"Am J Neurodegener Dis"},{"key":"306_CR51","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2147\/OPTH.S92359","volume":"9","author":"RP Danis","year":"2015","unstructured":"Danis RP, Lavine JA, Domalpally A (2015) Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol 9:2159\u20132174","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"306_CR52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2006.11.041","volume":"143","author":"FG Holz","year":"2007","unstructured":"Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S, FAM-Study Group (2007) Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 143(3):463\u2013472","journal-title":"Am J Ophthalmol"},{"key":"306_CR53","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ophtha.2008.03.008","volume":"115","author":"Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group","year":"2008","unstructured":"Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group (2008) Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 115:1474\u20131479, 1479.e1\u20136","journal-title":"Ophthalmology"},{"issue":"9","key":"306_CR54","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ophtha.2013.01.049","volume":"120","author":"HS Brader","year":"2013","unstructured":"Brader HS, Ying GS, Martin ER, Maguire MG, Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) Research Group (2013) Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 120(9):1871\u20131879","journal-title":"Ophthalmology"},{"issue":"3","key":"306_CR55","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1167\/iovs.14-16211","volume":"56","author":"Z Wu","year":"2015","unstructured":"Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2015) Fundus autofluorescence characteristics of nascent geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 56(3):1546\u20131552","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"306_CR56","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/eye.2012.107","volume":"26","author":"S Grob","year":"2012","unstructured":"Grob S, Luo J, Hughes G, Lee C, Zhou X, Lee J, Du H, Ferreyra H, Freeman WR, Kozak I, Zhang K (2012) Genetic analysis of simultaneous geographic atrophy and choroidal neovascularization. Eye (Lond) 26(8):1106\u20131113","journal-title":"Eye (Lond)"},{"key":"306_CR57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2015.09.032","volume":"161","author":"Y Kuroda","year":"2016","unstructured":"Kuroda Y, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Oishi A, Nakanishi H, Miyake M, Yoshikawa M, Yoshimura N (2016) Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. Am J Ophthalmol 161:94\u2013103.e1","journal-title":"Am J Ophthalmol"},{"key":"306_CR58","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ (2015) Subretinal Hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology 122:1846\u20131853.e5","journal-title":"Ophthalmology"},{"key":"306_CR59","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","volume":"159","author":"C Sch\u00fctze","year":"2015","unstructured":"Sch\u00fctze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2015) Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 159:1100\u20131114.e1","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"306_CR60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ajo.2014.12.010","volume":"159","author":"G Yiu","year":"2015","unstructured":"Yiu G, Chiu SJ, Petrou PA, Stinnett S, Sarin N, Farsiu S, Chew EY, Wong WT, Toth CA (2015) Relationship of central choroidal thickness with age-related macular degeneration status. Am J Ophthalmol 159(4):617\u2013626","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"306_CR61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1755-3768.2011.02179.x","volume":"90","author":"K Kinnunen","year":"2012","unstructured":"Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K (2012) Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol 90(4):299\u2013309","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"306_CR62","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bjophthalmol-2013-303219","volume":"97","author":"M Karampelas","year":"2013","unstructured":"Karampelas M, Sim DA, Keane PA, Papastefanou VP, Sadda SR, Tufail A, Dowler J (2013) Evaluation of retinal pigment epithelium-Bruch\u2019s membrane complex thickness in dry age-related macular degeneration using optical coherence tomography. Br J Ophthalmol 97(10):1256\u20131261","journal-title":"Br J Ophthalmol"},{"key":"306_CR63","doi-asserted-by":"publisher","first-page":"768026","DOI":"10.1155\/2014\/768026","volume":"2014","author":"J Blasiak","year":"2014","unstructured":"Blasiak J, Petrovski G, Ver\u00e9b Z, Facsk\u00f3 A, Kaarniranta K (2014) Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration. Biomed Res Int 2014:768026. doi:10.1155\/2014\/768026","journal-title":"Biomed Res Int"},{"key":"306_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","volume":"45","author":"SS Whitmore","year":"2015","unstructured":"Whitmore SS, Sohn EH, Chirco KR, Drack AV, Stone EM, Tucker BA, Mullins RF (2015) Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45:1\u201329","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"306_CR65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jcp.10026","volume":"189","author":"K Ohno-Matsui","year":"2001","unstructured":"Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189(3):323\u2013333","journal-title":"J Cell Physiol"},{"issue":"1","key":"306_CR66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00417-003-0828-0","volume":"242","author":"RO Schlingemann","year":"2004","unstructured":"Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242(1):91\u2013101","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"306_CR67","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)61231-X","volume":"167","author":"AG Marneros","year":"2005","unstructured":"Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167(5):1451\u20131459","journal-title":"Am J Pathol"},{"issue":"2","key":"306_CR68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/bjophthalmol-2011-301087","volume":"96","author":"K Manousaridis","year":"2012","unstructured":"Manousaridis K, Talks J (2012) Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? Br J Ophthalmol 96(2):179\u2013184","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"306_CR69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171(1):53\u201367","journal-title":"Am J Pathol"},{"issue":"11","key":"306_CR70","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D\u2019Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on M\u00fcller cells and photoreceptors. PLoS ONE 3(11):e3554","journal-title":"PLoS ONE"},{"issue":"13","key":"306_CR71","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1167\/iovs.11-8353","volume":"52","author":"KM Ford","year":"2011","unstructured":"Ford KM, Saint-Geniez M, Walshe T, Zahr A, D\u2019Amore PA (2011) Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 52(13):9478\u20139487","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"306_CR72","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajo.2015.05.030","volume":"160","author":"I Zucchiatti","year":"2015","unstructured":"Zucchiatti I, Parodi MB, Pierro L, Cicinelli MV, Gagliardi M, Castellino N, Bandello F (2015) Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration. Am J Ophthalmol 160:602\u2013607.e1","journal-title":"Am J Ophthalmol"},{"issue":"7252","key":"306_CR73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature08151","volume":"460","author":"A Takeda","year":"2009","unstructured":"Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460(7252):225\u2013230","journal-title":"Nature"},{"issue":"4","key":"306_CR74","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","volume":"122","author":"MC Peden","year":"2015","unstructured":"Peden MC, Su\u00f1er IJ, Hammer ME, Grizzard WS (2015) Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 122(4):803\u2013808","journal-title":"Ophthalmology"},{"issue":"11","key":"306_CR75","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292\u20132299","journal-title":"Ophthalmology"},{"issue":"7","key":"306_CR76","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"19","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 19(7):1388\u20131398","journal-title":"Ophthalmology"},{"issue":"9900","key":"306_CR77","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC, IVAN study investigators (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2\u2011year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258\u20131267","journal-title":"Lancet"},{"issue":"4","key":"306_CR78","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160(4):725\u2013731 (e1)","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"306_CR79","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1358\/dot.2012.48.5.1805931","volume":"48","author":"EA Verner-Cole","year":"2012","unstructured":"Verner-Cole EA, Davis SJ, Lauer AK (2012) Aflibercept for the treatment of neovascular age-related macular degeneration. Drugs Today 48(5):317\u2013329","journal-title":"Drugs Today"},{"key":"306_CR80","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2013.02.012","volume":"156","author":"SB Bloch","year":"2013","unstructured":"Bloch SB, Lund-Andersen H, Sander B, Larsen M (2013) Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Am J Ophthalmol 156:116\u2013124.e1","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"306_CR81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","volume":"118","author":"PJ Rosenfeld","year":"2011","unstructured":"Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B, MARINA and ANCHOR Study Groups (2011) Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 118(3):523\u2013530","journal-title":"Ophthalmology"},{"issue":"7","key":"306_CR82","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/aos.12781","volume":"93","author":"A Rasmussen","year":"2015","unstructured":"Rasmussen A, Brandi S, Fuchs J, Hansen LH, Lund-Andersen H, Sander B, Larsen M (2015) Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol 93(7):616\u2013620","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"306_CR83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF, CATT Research Group (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121(1):150\u2013161","journal-title":"Ophthalmology"},{"key":"306_CR84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","volume":"159","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, Kim JW (2015) Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159:285\u201392.e1","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"306_CR85","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00417-010-1483-x","volume":"249","author":"SS Mann","year":"2011","unstructured":"Mann SS, Rutishauser-Arnold Y, Peto T, Jenkins SA, Leung I, Xing W, Bird AC, Bunce C, Webster AR (2011) The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD). Graefes Arch Clin Exp Ophthalmol 249(2):209\u2013214","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"306_CR86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2014.09.012","volume":"159","author":"R Channa","year":"2015","unstructured":"Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, Campochiaro PA (2015) Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am J Ophthalmol 159:9\u201319.e1\u20132","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"306_CR87","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1136\/bjophthalmol-2014-306338","volume":"99","author":"E Pilotto","year":"2015","unstructured":"Pilotto E, Guidolin F, Convento E, Stefanon FG, Parrozzani R, Midena E (2015) Progressing geographic atrophy: choroidal thickness and retinal sensitivity identify two clinical phenotypes. Br J Ophthalmol 99(8):1082\u20131086","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"306_CR88","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1167\/iovs.15-17366","volume":"56","author":"E Pilotto","year":"2015","unstructured":"Pilotto E, Guidolin F, Convento E, Antonini R, Stefanon FG, Parrozzani R, Midena E (2015) En face optical coherence Tomography to detect and measure geographic atrophy. Invest Ophthalmol Vis Sci 56(13):8120\u20138124","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"306_CR89","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14740338.2014.939951","volume":"13","author":"JM Gibson","year":"2014","unstructured":"Gibson JM, Gibson SJ (2014) A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. Expert Opin Drug Saf 13(9):1259\u20131270","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"306_CR90","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","volume":"120","author":"A Rasmussen","year":"2013","unstructured":"Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M, Lund-Andersen H, Sander B (2013) A 4\u2011year longitudinal study of 555 patients treated with Ranibizumab for neovascular age-related macular degeneration. Ophthalmology 120(12):2630\u20132636","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"306_CR91","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/eye.2015.77","volume":"29","author":"M McKibbin","year":"2015","unstructured":"McKibbin M, Devonport H, Gale R, Gavin M, Lotery A, Mahmood S, Patel PJ, Ross A, Sivaprasad S, Talks J, Walters G (2015) Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye (Lond) 29(Suppl 1):S1\u2013S11","journal-title":"Eye (Lond)"},{"issue":"1","key":"306_CR92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122(1):146\u2013152","journal-title":"Ophthalmology"},{"issue":"11","key":"306_CR93","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00417-013-2338-z","volume":"251","author":"SY Cohen","year":"2013","unstructured":"Cohen SY, Dubois L, Ayrault S, Dourmad P, Delahaye-Mazza C, Fajnkuchen F, Nghiem-Buffet S, Quentel G, Tadayoni R (2013) Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol 251(11):2499\u20132503","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"306_CR94","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, Mc Allister IL, Essex RW, Morlet N, Gillies MC, Fight Retinal Blindness Study Group (2015) Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 122(6):1212\u20131219","journal-title":"Ophthalmology"},{"issue":"8","key":"306_CR95","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mon\u00e9s J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A literature review and consensus recommendations. Retina 35(8):1489\u20131506","journal-title":"Retina"},{"issue":"1","key":"306_CR96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ophtha.2014.07.046","volume":"122","author":"E Tanaka","year":"2015","unstructured":"Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM (2015) Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology 122(1):153\u2013161","journal-title":"Ophthalmology"},{"issue":"7","key":"306_CR97","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/eye.2014.100","volume":"28","author":"EJ Sigler","year":"2014","unstructured":"Sigler EJ, Randolph JC, Calzada JI, Charles S (2014) Smoking and choroidal thickness in patients over 65 with early-atrophic age-related macular degeneration and normals. Eye (Lond) 28(7):838\u2013846","journal-title":"Eye (Lond)"},{"issue":"3","key":"306_CR98","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/ICU.0000000000000050","volume":"25","author":"A Rasmussen","year":"2014","unstructured":"Rasmussen A, Sander B (2014) Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. Curr Opin Ophthalmol 25(3):158\u2013163","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"306_CR99","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bjophthalmol-2013-304775","volume":"98","author":"MN Menke","year":"2014","unstructured":"Menke MN, Zinkernagel MS, Ebneter A, Wolf S (2014) Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. Br J Ophthalmol 98(9):1197\u20131200","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"306_CR100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/13543784.2015.961601","volume":"24","author":"MJ Tolentino","year":"2015","unstructured":"Tolentino MJ, Dennrick A, John E, Tolentino MS (2015) Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin Investig Drugs 24(2):183\u2013199","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"306_CR101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/08820538.2013.835833","volume":"30","author":"R Nuzzi","year":"2015","unstructured":"Nuzzi R, Tridico F (2015) Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Semin Ophthalmol 30(2):129\u2013135","journal-title":"Semin Ophthalmol"},{"issue":"11","key":"306_CR102","first-page":"3843","volume":"7","author":"Y Mu","year":"2014","unstructured":"Mu Y, Zhao M, Su G (2014) Stem cell-based therapies for age-related macular degeneration: current status and prospects. Int J Clin Exp Med 7(11):3843\u20133852","journal-title":"Int J Clin Exp Med"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-016-0306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0306-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T12:29:04Z","timestamp":1568118544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-016-0306-9"}},"subtitle":["Unausweichliche Folge der anti-VEGF-Therapie ?"],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s00347-016-0306-9","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}